12 Consumer Discretionary Stocks Moving In Thursday’s After-Market Session

Gainers Genius Gr (AMEX:GNS) stock increased by 19.9% to $0.33 during Thursday’s after-market session. The company’s market cap…

Gainers

  • Genius Gr (AMEX:GNS) stock increased by 19.9% to $0.33 during Thursday’s after-market session. The company’s market cap stands at $65.1 million.
  • Sypris Solutions (NASDAQ:SYPR) stock rose 7.87% to $1.78. The market value of their outstanding shares is at $40.5 million.
  • Nerdy (NYSE:NRDY) shares moved upwards by 5.19% to $1.62. The company’s market cap stands at $176.5 million.
  • Kaixin Hldgs (NASDAQ:KXIN) stock rose 3.86% to $0.16. The company’s market cap stands at $9.2 million.
  • Purple Innovation (NASDAQ:PRPL) stock moved upwards by 3.41% to $1.21. The company’s market cap stands at $130.0 million.
  • Revolve Gr (NYSE:RVLV) stock increased by 3.12% to $18.5. The market value of their outstanding shares is at $1.3 billion.

Losers

  • Boqii Holding (AMEX:BQ) shares fell 10.3% to $0.35 during Thursday’s after-market session. The company’s market cap stands at $1.6 million.
  • Barnes & Noble Education (NYSE:BNED) shares decreased by 7.0% to $0.3. The market value of their outstanding shares is at $16.0 million.
  • Tilly’s (NYSE:TLYS) stock declined by 6.9% to $5.4. The market value of their outstanding shares is at $162.3 million. As per the press release, Q1 earnings came out today.
  • Jiuzi Hldgs (NASDAQ:JZXN) shares declined by 6.48% to $0.36. The market value of their outstanding shares is at $42.4 million.
  • Vail Resorts (NYSE:MTN) shares fell 4.88% to $184.5. The company’s market cap stands at $7.0 billion. As per the press release, Q3 earnings came out today.
  • BARK (NYSE:BARK) stock decreased by 4.77% to $1.4. The market value of their outstanding shares is at $245.8 million. As per the news, the Q4 earnings report came out 3 days ago.
    See Also: www.benzinga.com/money/best-consumer-cyclical-stocks/

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

What’s Going On With Crispr Therapeutics Stock?

Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares have risen nearly 37% over the past month following the FDA approval of Casgevy (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older on Jan. 16.

CRSP